Classifications

• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
  • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
  • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
  • C12Q1/24—Methods of sampling, or inoculating or spreading a sample; Methods of physically isolating an intact microorganisms
• • G—PHYSICS
  • G01—MEASURING; TESTING
  • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
  • G01N1/00—Sampling; Preparing specimens for investigation
  • G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
  • G01N1/40—Concentrating samples
  • G01N1/405—Concentrating samples by adsorption or absorption

Definitions

• Sepsis is a serious medical condition caused by an overwhelming response of the host immune system to infection. It can trigger widespread inflammation, which can give rise to impaired blood flow. As sepsis progresses, the body's organs can be starved for oxygen and nutrients, causing permanent damage and eventual failure. Left improperly diagnosed or otherwise untreated, the heart weakens and septic shock can occur, leading to multiple organ failure and death. Blood cultures are required to detect and identify the presence of microorganism ( s ) in the patient and guide treatment. Current methods of isolating the microorganism often require sub-culturing the microorganism from the positive blood culture sample.
• AST antimicrobial susceptibility testing
• current methods take at least 24 to 48 hours to perform, which results in many of the septicemia patients being initially treated with inappropriate antibiotics .
• PBCs Positive blood cultures
• s Positive blood cultures
• PBCs have a high protein and salt content, contain a large amount of organic particles, including various types of blood cells, as well as the sepsis-causing microorganism ( s ) .
• certain downstream testing, for example AST requires viable microorganism ( s ) in order to obtain accurate results.
• Filtration-based methods using 0.2 ⁇ filters are commonly used in laboratories to sterilize liquids that may be contaminated with low levels of bacteria. Such filtration is, however, often not successful for capturing bacteria from PBCs or whole blood because these samples contain a large amount of organic particulate material such as blood cells along with the microorganism to be analyzed. These organic particulate materials often clog the filter, preventing adequate filtration, and ultimately interfere with downstream detection and/or analysis of the sample to determine the presence or absence of microorganism therein.
• diatomaceous earth particles including
• Kshirsagar I describes the use of diatomaceous earth treated with an adsorption buffer-modified solution, such as a cation-containing salt, and complexed to a metal for concentrating microorganisms .
• Kshirsagar II describes the use of unmodified diatomaceous earth or diatomaceous earth modified with titanium dioxide, gold, or platinum as a concentration agent to bind microorganisms in a sample.
• the microorganism can be removed from the diatomaceous earth particles by sonication, or by chemical treatment with bovine serum albumin ("BSA") .
• BSA bovine serum albumin
• BSA interferes with certain downstream testing, such as identification by mass spectrometry.
• Sub-culturing is a time-consuming method which does not provide the needed fast determination for patients with suspected sepsis .
• Methods described herein provide for the rapid isolation, purification, and concentration of microorganism ( s ) from various types of samples for use in downstream biochemical analyses and/or identification methods by removing or reducing interfering substances or particulate matter in the complex matrix of the sample.
• the described methods include obtaining a sample known to contain at least one microorganism and mixing the sample with sorbent material that is capable of capturing the microorganism. After mixing the sample with the sorbent material, the suspension is applied to a column where the microorganism is captured by the sorbent inside the column. The sorbent-captured microorganism is then washed to remove unwanted substances in the sample while retaining the microorganism. The captured microorganism is then used for subsequent analysis and characterization of the microorganism .
• viable microorganism in the sample is recovered and further analysis is performed without a need to subculture the microorganism.
• microorganism is first captured by a sorbent material which can be removed prior to downstream analysis of the microorganism. At least some of the microorganisms so removed remains viable afterwards .
• the downstream analysis does not require viable microorganisms, the constituents of the microorganism (e.g. proteins and nucleic acids) can be extracted while bound to the sorbent material. Therefore, the methods of the present invention contemplate the removal of substances in the sample that may interfere with downstream analyses (e.g. the removal of blood components in a PBC sample that may interfere with MALDI-TOF MS identification) in addition to preserving viability of microorganisms for downstream testing when required.
• downstream analyses e.g. the removal of blood components in a PBC sample that may interfere with MALDI-TOF MS identification
• the methods described herein contemplate the use of a variety of methods and reagents used for the recovery and/or analysis of the microorganism once captured by the sorbent material. These methods and reagents can be customized for the particular downstream assay or analysis to be performed.
• FIG. 1 illustrates one embodiment in which viable microorganism is isolated and concentrated from a PBC sample using sorbent material and subsequently used for AST testing and identification.
• FIG. 2 illustrates another embodiment in which viable microorganism is isolated and concentrated from a PBC sample using sorbent material and subsequently used for AST testing and identification.
• FIG. 3 illustrates one embodiment in which microorganism is isolated and concentrated from a PBC sample using sorbent material and subsequently undergoes on-column extraction of the bound microorganism followed by MALDI-TOF MS identification.
• the methods described herein relate to the isolation, purification, and concentration of microorganism ( s ) from a sample for use in downstream analyses.
• the methods involve obtaining a sample known to contain at least one microorganism, mixing the sample with a sorbent material, applying the suspension to a column that may or may not contain a sorbent pre-coat layer, allowing the microorganism to be captured by the sorbent material while washing away unwanted substances in the sample, and using the captured microorganism for subsequent analysis.
• the methods allow for maintaining the viability of the microorganism without the need for subculturing .
• the microorganism can be extracted while captured by the sorbent .
• sorbent materials are known in the art and selection of a particular sorbent material depends upon the nature of the sample to be analyzed. It is to be understood that the capture of the microorganism by the sorbent material refers to the ability of the sorbent to trap and/or bind the microorganism without adversely affecting viability.
• binding refers to a chemical interaction such as those caused by a surface modification of the sorbent material which causes the microorganism to be captured by the sorbent through chemical interactions .
• “trapping” refers to the microorganism being captured by the sorbent material due to size restriction: i.e., the size of the microorganism, compared to the particle size of the sorbent material, enables the microorganism to be physically trapped by the sorbent material rather than "bound" by chemical interactions.
• the sorbent materials which may be used in the practice of the methods described herein, are composed of various particles sizes and various shapes.
• the sorbent materials that may be used are micro-porous .
• sorbent materials containing micropores allows for the formation of channels between the sorbent material particles as well as through the particles. The microorganism is trapped by the majority of the channels between the sorbent material while
• the liquid from the sample is able to flow through the pores in the sorbent material particles . This allows for the processing of larger sample volumes.
• the pore size in the sorbent material particle is smaller than the size of the microorganism to be captured.
• the sorbent materials that may be used in the described methods are physically rigid, i.e., the sorbent material cake formed in the column cannot be easily compressed under normal filtration pressure, allowing flow channels to remain open.
• the sorbent materials that may be used are optionally, chemically inert. If the sorbent materials are not inert, i.e., contain surface modifications that would cause the microorganism to bind to the sorbent material, rather than be trapped by it, removal of the microorganism from the sorbent material may require harsher reagents that could decrease viability and/or interfere with downstream analysis. However, if the downstream analysis does not require intact cells to be released from the column or cell viability to be maintained, non-inert sorbent materials can be used. It is also possible that non-inert sorbents may be blocked by components from the complex sample and thus be used in these methods .
• the amount of sorbent material used in the methods described herein is based on the volume of the sample to be processed. The more sample to be analyzed, the more volume of sorbent material is required to capture the microorganism in the sample.
• the ratio of sorbent material to sample volume affects the flow of the column and thus the capture efficiency of the microorganism.
• Each type of sorbent material has a different capacity for trapping a certain amount of microorganism in the sample per unit volume of sorbent material used. Therefore, the methods described herein contemplate the use of various ratios of sorbent material volume to sample volume, depending on sample complexity and the particular sorbent material being used.
• the sorbent material comprises diatomaceous earth particles.
• the sorbent material is the sorbent material commercially available under the trademark Celite®, which is a registered trademark of the Celite Corporation.
• the sorbent material comprises cellulose fibers or particles .
• FIG. 1 illustrates one exemplary embodiment in which the viability of microorganism is preserved after being isolated and concentrated from a PBC sample using sorbent material.
• a sample known to contain at least one microorganism is obtained in step 100, for example a PBC sample, and mixed with a suspension containing sorbent material.
• the sample mixed with sorbent in step 100 is applied to a column in step 110 and flow is initiated in order to allow the microorganism in the sample obtained in step 100 to be captured by the sorbent material inside the column in step 115.
• the column can be prepared with a sorbent material pre-coat layer in step 105 by adding the sorbent material in a liquid suspension to the column containing a frit and allowing the liquid from the suspension to exit the column while the sorbent material is retained by the frit .
• other organic or liquid material in the sample can be separated from the microorganism by allowing the sample liquid to flow through the column, and/or by washing the column 120 containing the sorbent-captured sample in step 120.
• a suspension of the sorbent-captured microorganism is prepared in step 125 by adding a liquid reagent, for example Phoenix® ID broth, to the column and transferring the suspension in step 130 to a separate container.
• the suspension of step 125 is vortexed on step 135 to release the microorganism from the sorbent material, allowing the sorbent material to settle in step 140 at the bottom of the container while viable microorganism remains suspended 145 in the supernatant.
• Downstream analysis 150 for example BD Phoenix® ID/AST and/or MALDI-TOF MS identification, of suspended microorganism in step (from step 145) in the supernatant is performed in order to characterize the microorganism in sample obtained in step 100.
• Sample can be any sample known to contain at least one microorganism. Possible types of samples include, but are not limited to, body fluids, whole blood samples, positive blood cultures, urine, cerebrospinal fluid, environmental samples such as soil, and industrial samples.
• the type of microorganism in the sample is not limited.
• the methods described herein can be used to prepare and analyze various types of microorganisms in the sample, including, for example, bacteria, yeast, fungi and mycobacteria .
• the sample is mixed with a suspension of sorbent material prior to the applying step 110.
• the sorbent material suspension can comprise, for example, a suspension buffer containing water or a saline solution.
• the suspension buffer may include a lysis buffer containing, for example, saponins, Tweens®, TritonsTM, ammonium chloride, lytic culture medias, or mixtures thereof.
• the optional pre-coat layer is washed with a wash buffer prior to mixing with the sample.
• the wash buffer is compatible with the downstream assay, i.e., the wash buffer does not interfere with obtaining accurate and consistent results.
• the wash buffer is a saline solution or water.
• the wash buffer may include a lysis buffer containing, for example, saponins, Tweens®, TritonsTM, ammonium chloride, lytic culture medias, or mixtures thereof.
• microorganism captured by the sorbent material in step 115 is washed in step 120 with a wash buffer prior to creating a suspension of sorbent- captured microorganism in step 125. This wash step may help provide more accurate results by removing unbound substances in the sample that interfere with the downstream assay and by using a wash buffer that is compatible with the downstream assay.
• the wash buffer is BD
• the wash buffer may include a lysis buffer containing, for example, saponins, Tweens®, TritonsTM, ammonium chloride, a lytic culture, or mixtures thereof.
• the washing step can comprise a single wash or multiple rounds of washing. Multiple rounds of washing can be accomplished with a single type of wash buffer or with multiple wash buffers.
• the methods described herein contemplate optimizing the subsequent reagents and processing steps for the particular downstream assay to be used.
• the methods include recovering viable or non-viable microorganism from the sorbent material.
• the type of downstream assay which can be conducted is not limited, and can include, for example, growth-based and non-growth-based methods, biochemical assays, identification techniques such as MALDI-TOF MS and
• BD MAXTM is a trademark of Becton Dickinson and
• the methods described herein can prepare a common sample containing one or more microorganisms (e.g. bacteria) for multiple downstream analyses, including both growth-based and non-growth based methods.
• one sample known to contain microorganisms is divided into portions, each portion is mixed with a sorbent material, each of the sorbent-microorganism suspensions is applied to a separate column, and each of the sorbent-captured microorganism eluents is used for a different downstream analysis .
• one sample known to contain microorganisms is mixed with a sorbent material, the sorbent- microorganism suspension is applied to a single column, the microorganism is eluted from the sorbent material, and a portion of the microorganism-containing eluent is used for one downstream analysis while another portion is used for a different downstream analysis .
• microorganism captured by the sorbent material in the column is recovered from the sorbent material by creating a suspension by adding a suspension buffer to the microorganism captured in step 115 by the sorbent material while the column exit is closed.
• cell viability is maintained upon addition of the suspension buffer.
• Suspension buffers can include, for example, water or BD Phoenix® ID broth at various concentrations, or detergent-containing lysis buffers.
• the suspension buffer contains buffers known to those skilled in the art that support viability, growth and detection of the microorganism and are not described in detail herein.
• the suspension is transferred in step 130 to another container and vortexed in step 135 in order to separate the microorganism from the sorbent material. After vortexing the supernatant contains viable microorganism while the sorbent material settles at the bottom of the container.
• the suspension can be vortexed or mixed while still inside the column .
• FIG. 2 illustrates one exemplary embodiment in which the viability of microorganism is preserved after being isolated and concentrated from a PBC sample using sorbent material.
• a sample known to contain at least one microorganism is obtained in step 200.
• the sample for example a PBC sample, is mixed with a suspension of sorbent material.
• the sample mixed with sorbent material in step 200 is applied to a column in step 210 in order to allow the microorganism in the sample to be captured by the sorbent material inside the column in step 215.
• the column can be prepared with a sorbent pre-coat layer (step 205) by adding the sorbent material in a liquid suspension to the column containing a frit and allowing the liquid from the suspension to exit the column while the sorbent material is retained by the frit.
• a sorbent pre-coat layer step 205 by adding the sorbent material in a liquid suspension to the column containing a frit and allowing the liquid from the suspension to exit the column while the sorbent material is retained by the frit.
• other organic or liquid material in the sample can be separated from the microorganism by allowing the sample liquid to flow through the column, and/or by washing the column (step 220) containing the sorbent-captured sample.
• the captured microorganism is released from the sorbent material by adding a buffer in step 225 to the sorbent containing captured microorganism (washed in step 220) to create a suspension of sorbent material and released microorganism.
• the sorbent material is allowed to settle in step 230 and the viable, concentrated microorganism is retrieved from the supernatant 235.
• Downstream analysis of the microorganism is performed in step 245 (e.g., Phoenix ID/AST and/or MALDI-TOF MS identification) .
• the microorganism is extracted while captured by the sorbent material inside the column using an on-column extraction method.
• an on-column extraction method is illustrated in FIG. 3.
• Captured microorganism is obtained in step according to any of the methods described herein using a column that may optionally contain a sorbent pre-coat layer .
• Captured microorganism from step 300 is washed with an organic solvent in step 310, such as for example, 70% ethanol in water by applying the ethanol to the column, allowing the ethanol to flow over the sorbent-bound microorganism and through the column, and discarding the flow-through.
• an organic solvent such as for example, 70% ethanol in water
• Captured and washed microorganism is then extracted in step 320 directly in the column by applying an acid, such as, for example, 70% formic acid in water, to the column.
• the formic acid comes in contact with sorbent-captured microorganism, thereby extracting the microorganism, and flows through the column.
• the flow-through from extraction in step 320 is collected in step 330 and analyzed in step 340 by MALDI-TOF MS for microbial identification.
• a second extraction step 350 is optionally performed by applying a 1:1 solution of 70% formic acid in acetonitrile to the column and allowing the solution to come in contact with any residual washed sorbent-bound microorganism from step 310 not extracted during first extraction step 320.
• the formic acid/acetonitrile comes in contact with any residual microorganism, extracting the residual microorganism and flows through the column.
• the flow-through from second extraction step 350 is collected in step 360, combined with the flow-through from 330 from the first extraction step 320, and analyzed in step 340 by MALDI-TOF MS for microbial identification.
• flow-through from the second extraction step 350 is collected and analyzed by MALDI-TOF MS identification in step 370 without combining the flow-through from the first and second extractions before identification .
• the sample known to contain at least one microorganism is whole blood or a positive blood culture sample.
• the red blood cells in the sample are lysed prior to performing capture by the sorbent material.
• capture of the microorganism by the sorbent material in the whole blood or PBC is performed on un-lysed blood samples.
• lysis of the blood cells can optionally be performed in the column. Methods for lysing red blood cells are well known to those skilled in the art and are not described in detail herein.
• EXAMPLE 1 Capture of Escherichia coli (E. coli) from a saline solution using Celite® followed by MALDI-TOF MS identification
• the Celite®-trapped bacteria was washed with 2 ml of BD Phoenix® ID broth (Becton Dickinson and Company catalog number 246001) followed by a wash with 2 ml of sterile water. The wash cycle with BD Phoenix® ID broth and water was repeated one time.
• BD Phoenix® ID broth Becton Dickinson and Company catalog number 246001
• DPBS Dulbecco's phosphate buffered saline
• the washed Celite®-trapped bacteria was removed from the column by adding 1 ml of sterile water to the column containing the Celite®-trapped bacteria to create a suspension, and the Celite®-bacteria suspension was transferred to a clear glass tube.
• the glass tube containing the Celite®-bacteria suspension was vortexed briefly to remove the bacteria from the Celite® particles and to resuspend the captured bacteria in the water. After vortexing, the mixture was allowed to stand for approximately 10 to 60 minutes to allow the Celite® particles to settle to the bottom of the tube. The resulting supernatant contained resuspended, viable bacteria.
• a portion of the supernatant (1 to 2 ⁇ ) containing the resuspended bacteria was analyzed by MALDI-TOF MS on a Bruker Microflex MALDI-TOF for bacterial identification.
• the MALDI matrix solution was prepared by dissolving 2.5 mg of HCCA in 250 ⁇ ⁇ of a solution that is 2.5% trifluoroacetic acid, 47.5% deionized water, and 50% acetonitrile . All of the mass spectrometry data was recorded on Bruker Microflex LT with Biotyper software with the following MALDI score key definition.
• a MALDI ID score of greater than 2.0 indicates a satisfactory identification to the Genus and Species level.
• a MALDI ID score of 1.7-1.999 indicates a satisfactory identification to the Genus level.
• a MALDI ID score of less than 1.699 indicates an unacceptable or not reliable identification .
• MALDI-TOF analysis resulted in a positive identification of E. coli ATCC 25922 with a score of 2.2 indicating identification to the species level.
• Flow-through analysis of the capture and wash steps did not reveal any viable bacterial counts, indicating efficient capture of E. coli by the Celite® particles.
• Comparison of the viability count of the Celite®-bacteria suspension with that of the original sample indicated at least 47% of the viable counts from the original sample are present in the suspension.
• EXAMPLE 2 Capture of Staphylococcus aureus ⁇ S. aureus) from a blood sample using Celite® followed by Phoenix® identification and AST.
• a BACTEC plus aerobic/F bottle (Becton Dickinson and Company catalog number 442192) was spiked with 10 ml human blood and sufficient S. aureus (ATCC 29213) to create a BACTEC plus aerobic/F bottle (Becton Dickinson and Company catalog number 442192) was spiked with 10 ml human blood and sufficient S. aureus (ATCC 29213) to create a BACTEC plus aerobic/F bottle (Becton Dickinson and Company catalog number 442192) was spiked with 10 ml human blood and sufficient S. aureus (ATCC 29213) to create a
• Celite® 535 (50% suspension in saline). The Celite®/bacteria suspension was added to the pre-coated Celite® column prepared below in three portions . The liquid was withdrawn from the column at a rate of 1 to 2 ml per minute with the aid of a syringe. A layer of Celite®-trapped bacteria was formed above the pre-coat layer at the bottom of the column.
• the Celite®-trapped bacteria was washed with 2 ml of Phoenix® ID broth followed by a wash with 2 ml of sterile water. The wash cycle with BD Phoenix ID broth and water was repeated one time.
• a Celite® pre-coat layer was prepared as in Example
• the Celite®-trapped bacteria was removed from the column by adding 4.5 ml Phoenix® ID broth to the column to create a suspension, and the Celite®-bacteria suspension was transferred to a clear glass tube.
• the glass tube containing the Celite®-trapped bacteria suspension was vortexed briefly to remove the bacteria from the Celite® particles and to resuspend bacteria in the Phoenix® ID broth. After vortexing, the mixture was allowed to stand for approximately 10 to 60 minutes to allow the Celite® particles to settle to the bottom of the tube. The resulting supernatant contained resuspended, viable bacteria.
• a portion of the supernatant (approximately 4 ml) containing the resuspended bacteria was directly used to inoculate the gram positive ID-105 ID panel of the BD Phoenix® ID/AST system followed by a standard dilution to inoculate the AST panel.
• the Phoenix® ID/AST System is described in, e.g., U.S. Patent Nos. 5,922,593, 6,096,272, 6,372,485, 6,849,422, and 7,115,384, the contents of which are hereby incorporated by reference in their entirety .
• EXAMPLE 3 Capture of Staphylococcus aureus ⁇ S. aureus) from a blood sample using Celite® followed by on- column extraction and MALDI-TOF MS identification.
• Celite® 535 pre-coat layer prepared below and as in Example 2.
• a Celite® 535 pre-coat layer was prepared as in
• a portion (1 to 2 ⁇ ) of the formic acid flow- through was analyzed for bacterial identification by MALDI- TOF MS using a Bruker Microflex MALDI-TOF MS as described above.
• a second on-column extraction step was performed in the same manner as the first extraction step except that a 1:1 ratio of acetonitrile/70% formic acid in water was used.
• a portion (1 to 2 ⁇ ) of the flow-through from the second extraction step was also analyzed for bacterial identification by MALDI-TOF MS.
• MALDI-TOF MS analysis of the flow-through from the first extraction step with formic acid alone resulted in a positive identification of S. aureus ATCC 29213 with a score of 2.0 indicating identification to the species level.
• MALDI-TOF MS analysis of the flow-through from the second extraction step with acetonitrile and formic acid also resulted in a positive identification of S. aureus ATCC 29213 with a score in the range of 1.7 - 2.0.
• EXAMPLE 4 Capture of S. aureus from a single PBC sample using Hyflo Super Cel followed by Phoenix ID/AST and MALDI-TOF MS identification
• a BACTEC plus aerobic/F blood culture bottle was inoculated with 10-100 cfu S. aureus ATCC 29213 and 10 ml blood and allowed to incubate until positive in a BACTEC FX instrument.
• a first portion of this suspension was applied to one of the Celite® pre-coat layer columns prepared below and used for Phoenix ID/AST while a second portion of the suspension was applied to the second Celite® pre-coat layer column prepared below and used for MALDI-TOF MS identification .
• the Celite®-trapped bacteria was removed from the columns by adding 4.5 ml BD Phoenix® ID broth to the column to create a Celite®-bacteria suspension, and transferring the
• Celite®-bacteria suspension to a clear glass tube.
• the glass tube containing the Celite®-bacteria suspension was vortexed briefly to remove the bacteria from the Celite® particles and to resuspend the bacteria in the Phoenix® ID broth. After vortexing, the mixture was allowed to stand for approximately
• Example 5 Lysis of whole blood containing microorganisms followed by capture of the microorganisms with sorbent material.
• a suspension of sorbent material at a concentration of 50% was prepared with Celite® 535 sorbent material (Sigma- Aldrich catalog number 22138) .
• a portion of the sorbent material suspension (2 ml) was added to 10 ml of the lysed whole blood prepared above and loaded in three portions onto the column prepared below containing a sorbent material pre- coat layer.
• the liquid flow-through was collected and the volume of flow-through was measured.
• the column was then washed with 2 ml of Phoenix® ID broth.
• the flow-through from the wash step was collected, combined with the flow-through from the sample application step, and analyzed for cell viability before being discarded.
• a 50% suspension (1 ml) of Celite® 535 sorbent material in 70% ethanol in water was added to a 5 ml disposable plastic column containing a 30 ⁇ pore size polyethylene frit disc. The liquid was withdrawn from the bottom of the column forming a layer of sorbent material on the column frit. The sorbent material coating layer was washed with Dulbecco's phosphate buffered saline (DPBS) to stabilize and equilibrate the layer.
• DPBS Dulbecco's phosphate buffered saline
• the washed, sorbent-trapped bacteria were removed from the column by adding 3 ml of Phoenix® ID broth to the column to create a suspension. Three portions of ⁇ each of the suspension were used to perform a plate count of viable colonies.
• Results are summarized in Table 1 below.
• the capture efficiency of viable bacteria when using Celite® 535 as a sorbent material was in the range of approximately 62 to 93%.
• 48 to 61% of the original viable cells were recovered from the Celite® particles.
• Example 6 Capture and Recovery of Viable Bacteria
• a portion of a PBC sample (20 ml) containing E. faecalis was withdrawn from a PBC bottle and treated with 2 ml of 20% choline chloride in water for 5 minutes.
• a lysis buffer (20 ml) containing 0.66% TritonTM X-100 in lytic-10 broth was added to the sample and allowed to incubate for 5 minutes in order to lyse the blood cells in the PBC sample.
• a portion of the lysed sample (10 ml) was combined with 2 ml of a 50% suspension of either Sigmacell® Cellulose (50 ⁇ ) or Sigmacell® Cellulose (20 ⁇ ) .
• the sample/cellulose mixture (12 ml) was added to each of the three columns prepared below to capture the microorganism in the sample.
• the trapped microorganism was washed with 2 ml of 0.33% TritonTM X-100 in lytic-10 broth followed by a wash with 9 ml of Phoenix® ID broth.
• the preparation procedure was repeated using a negative blood culture sample ("NBC") as a control, i.e., a sample known to be negative for microorganisms .
• NBC negative blood culture sample
• Duplicate suspensions (1 ml each) at a concentration of 50% were made with each of Sigmacell® Cellulose 50 ⁇ and Sigmacell® Cellulose 20 ⁇ . Each suspension was applied to a 5 ml disposable plastic column containing a 30 ⁇ pore size polyethylene frit disc. The liquid was withdrawn from the bottom of the column forming a layer of cellulose on the column frit. The cellulose layer was washed with 10 ml of Dulbecco's phosphate buffered saline (DPBS) to stabilize and equilibrate the particle layer. The DPBS was withdrawn from the bottom of the column to form a cellulose pre-coat layer.
• DPBS Dulbecco's phosphate buffered saline
• the cellulose-trapped bacteria was removed from the column by adding 6 ml Phoenix® ID broth to the column to create a suspension, vortexing the sample, allowing the mixture to settle for 40 minutes, then performing a slow centrifugation of the supernatant at 750 rpm for 5 minutes. A portion of the supernatant containing the resuspended bacteria was used directly, or diluted to 0.5 McFarland, for identification and AST using the BD Phoenix® ID/AST system. The same method was applied to the columns containing the NBC samples .
• Table 2 Isolation and recovery of viable microorganism using cellulose sorbent material .
• a BACTEC plus aerobic/F blood culture bottle was inoculated with 10-100 cfu of S. aureus (ATCC 29213) and 10 ml of blood and allowed to incubate until a positive signal was formed in a BACTEC FX instrument.
• a portion of the PBC sample (20 ml) was withdrawn from the PBC bottle and mixed with 20 ml of lytic reagent containing 0.66% TritonTM X-100 in Bactec Lytic 10 media. After mixing for 10 minutes, the lysed PBC sample was divided into two equal portions. One of the 20 ml portions of the lysed PBC sample was applied directly onto the column prepared below containing a Celite® pre-coat layer.
• a disposable plastic column (20 ml size) with a 20 ⁇ polyethylene frit was pre-coated using 4.5 ml 50% suspension of Hyflo Super Cel® particles (Sigma Aldrich catalog number 56678) using the same method as described in Example 1 to form a Celite® pre-coat layer.
• the column containing the Hyflo Super Cel® pre-coat layer was used for capturing the lysed PBC sample that was not pre-mixed with sorbent material.
• a vacuum manifold was used to initiate column flow.
• a second column was prepared without a sorbent material pre-coat layer by washing a column with DPBS .
• the second column without a pre-coat layer was used to capture lysed PBC sample that was pre-mixed with Hyflo Super Cel® sorbent material.
• a vacuum manifold was used to initiate column flow.
• Sample capture on the two columns was initiated simultaneously by applying the two columns to vacuum manifold and allowing the sample to flow through the column. If the total sample volume flowed through the column, the column was washed with 4.5 ml of Phoenix® ID broth followed by a wash with 4.5 ml of water. The wash cycle with BD Phoenix ID broth and water was repeated one time.

Landscapes

• Chemical & Material Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Health & Medical Sciences (AREA)
• Organic Chemistry (AREA)
• Engineering & Computer Science (AREA)
• Zoology (AREA)
• Wood Science & Technology (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Analytical Chemistry (AREA)
• Pathology (AREA)
• Immunology (AREA)
• Microbiology (AREA)
• Molecular Biology (AREA)
• Biophysics (AREA)
• Physics & Mathematics (AREA)
• Biotechnology (AREA)
• Biochemistry (AREA)
• Bioinformatics & Cheminformatics (AREA)
• General Engineering & Computer Science (AREA)
• General Health & Medical Sciences (AREA)
• Genetics & Genomics (AREA)
• Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Applications Claiming Priority (2)

Publications (1)

Family

ID=49997754

Family Applications (1)

Country Status (1)

Cited By (1)

Citations (4)

• 2013
  • 2013-07-22 WO PCT/US2013/051454 patent/WO2014018435A1/fr not_active Ceased

Patent Citations (4)

Non-Patent Citations (2)

Similar Documents

Legal Events